Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2008
  • Online publication date: August 2009

9 - Spasticity and botulinum toxin


Botulinum toxin (BoNT) is the most potent neurotoxin known, and its clinical effects have been recognized since the end of 19th century. There are seven immunologically distinct serotypes of botulinum toxin; there are two types in routine clinical use - BoNT type A (BoNT-A) and BoNT type B (BoNT-B). Most of the large-scale studies on botulinum toxin have been related to upper and lower limb spasticity. The usefulness of BoNT in the management of spasticity secondary to a variety of clinical conditions is increasing. It is now well accepted for the management of movement disorders, particularly dystonia. There is an increasing evidence base for the use as a management tool in spasticity. The products now have a licence for use in focal spasticity. Dysport is indicated for focal spasticity specifically including arm symptoms associated with focal spasticity in conjunction with physiotherapy.
Ackman, J. D., Russman, B. S., Thomas, S. al. (2005). Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. Dev Med Child Neurol, 47: 620–7.
Bakheit, A. M. (2003). Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centres. Eur J Neurol, 10: 415–9.
Bakheit, A. M., Fedorova, N. V., Skoromets, A. al. (2004). The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry, 75: 1558–61.
Bakheit, A. M. & Sawyer, J. (2002). The effects of botulinum toxin treatment on associated reactions of the upper limb on hemiplegic gait: a pilot study. Disabil Rehabil, 24: 519–22.
Balkrishnan, R., Camacho, F. T., Smith, B. al. (2002). Cost impact of botulinum toxin use in Medicaid-enrolled children with cerebral palsy. J South Orthop Assoc, 11: 71–9.
Barnes, M. P., Best, D., Kidd, al. (2005). The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A: initial experiences. Eur J Neurol, 12: 947–55.
Benecke, R., Jost, W. H., Kanovsky, al. (2005). A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology, 64: 1949–51.
Bhakta, B. B., Cozens, J. A., Bamford, J. M. & Chamberlain, M. A. (1996). Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry, 61: 30–5.
Bhakta, B. B., Cozens, J. A., Chamberlain, M. A. & Bamford, J. M. (2000). Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry, 69: 217–21.
Blasi, J., Chapman, E., Link, al. (1993). Botulinum neurotoxin A selectively cleaves the synapse protein SNAP-25. Nature, 365: 160–3.
Bottos, M., Benedetti, M. G., Salucci, P., Gasparroni, V. & Giannini, S. (2003). Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment. Dev Med Child Neurol, 45: 758–62.
Brashear, A., Gordon, M. F., Elovic, al. (2002). Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med, 347: 395–400.
Brin, M. F. & Blitzer, A. (1993). Botulinum toxin: dangerous errors (letter). J R Soc Med, 86: 493–4.
Brin, M. F., Blitzer, A., Herman, S. & Stewart, C. (1994). Oromandibular dystonia: treatment of 96 patients with botulinum toxin type A. In: Jankovic, J., & Hallet, M. (eds.), Therapy with Botulinum Toxin. New York: Marcel Dekker, pp. 429–35.
Brin, M. F. & the Spasticity Study Group. (1997). Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Muscle Nerve, 20 (suppl. 6): S208–20.
Burgen, A. S. V., Dickens, F. & Zatman, L. J. (1949). The action of botulinum toxin on the neuromuscular junction. J Physiol, 109: 10–24.
Carda, S. & Molteni, F. (2005). Taping versus electrical stimulation after botulinum toxin type A injection for wrist and finger spasticity. A case-control study. Clin Rehabil, 19: 621–6.
Cardoso, E. S., Rodrigues, B. M., Barroso, al. (2006). Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy. Pediatr Neurol, 34: 106–9.
Childers, M. K., Brashear, A., Jozefczyk, al. (2004). Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil, 85: 1063–9.
Chin, T. Y., Nattrass, G. R., Selber, P. & Graham, H. K. (2005). Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Paediatr Orthop, 25: 286–91.
Das, T. K. & Park, D. M. (1989a). Botulinum toxin in treating spasticity. Br J Clin Pract, 43: 401–2.
Das, T. K. & Park, D. M. (1989b). Effect of treatment with botulinum toxin on spasticity. Postgrad Med J, 65: 208–10.
Dauer, W. T., Burke, R. E., Greene, P. & Fahn, S. (1998). Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain, 121: 547–60.
Dressler, D. & Eleopra, R. (2006). Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res, 9: 121–5.
Dunne, J. W., Heye, N. & Dunne, S. L. (1995). Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry, 58: 232–5.
Eleopra, R., Tugnoli, V., Rossetto, O., Montecuccu, C. & Grandis, D. (1997). Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett, 224: 91–4.
Eleopra, R., Tugnoli, V., Quatrale, al. (2006). Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F. Neurotox Res, 9: 127–31.
Fehlings, D., Rang, M., Glazier, J. & Steele, C. (2000). An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr, 137: 331–7.
Fock., J., Galea, M. P., Stillman, B. C., Rawicki, B. & Clark, M. (2004). Functional outcome following botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury. Brain Inj, 18: 57–63.
Frasson, E., Priori, A., Ruzzante, B., Didone, G. & Bertolasi, L. (2005). Nerve stimulation boosts botulinum toxin action in spasticity. Mov Disord, 20: 624–9.
Gordon, M. F., Brashear, A., Elovic, al. BOTOX Poststroke Spasticity Study Group. (2004). Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology, 63: 1971–3.
Grazko, M. A., Polo, K. B. & Jabbari, B. (1995). Botulinum toxin for spasticity, muscle spasms, and rigidity. Neurology, 45: 712–7.
Greene, P., Fahn, S. & Diamond, B. (1994). Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord, 9: 213–7.
Greene, P., Kang, U., Fahn, al. (1990). Double blind placebo controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology, 40: 1213–8.
Greene, P. E. & Fahn, S. (1993). Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord, 8: 479–83.
Hatheway, C. L. & Dang, C. (1994). Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic, J. & Hallett, M. (eds.), Therapy with Botulinum Toxin. New York: Marcel Dekker, pp. 93–108.
Hesse, S., Reiter, F., Konrad, M. & Jahnke, M. T. (1998). Botulinum toxin type A and short term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double blind, placebo controlled trial. Clin Rehab, 12: 381–8.
Houltram, J., Noble, I., Boyd, R. al. (2001). Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation. Eur J Neurol, 8 (suppl. 5): 194–202.
Houser, M. K., Sheean, G. L. & Lees, A. J. (1998). Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry, 64: 577–80.
Hsu, T. S., Dover, J. S. & Arndt, K. A. (2004). Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol, 140: 1351–4.
Jankovic, J. (1994). Botulinum toxin in movement disorders. Curr Opin Neurol, 7: 358–66.
Jankovic, J. & Schwartz, K. (1993). Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology, 43: 834–6.
Jitpimolmard, S., Tiamkao, S. & Laopaiboon, M. (1998). Long-term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry, 64: 751–7.
Johnson, C. A., Burridge, J. H., Strike, P. W., Wood, D. E. & Swain, I. D. (2004). The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation. Arch Phys Med Rehabil, 85: 902–9.
Jost, W. H., Kohl, A., Brinkmann, S. & Comes, G. (2005). Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm, 112: 905–13.
Kim, H. S., Hwang, J. H., Jeong, S. al. (2003). Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol, 45: 200–6.
Lee, L. R., Chuang, Y. C., Yang, B. J., Hsu, M. J. & Liu., Y. H. (2004). Botulinum toxin for lower limb spasticity in children with cerebral palsy: a single-blinded trial comparing dilution techniques. Am J Phys Med Rehabil, 83: 766–73.
Lim, E. C. H., Ong, B. K. C. & Seet, R. C. S. (2006). Botulinum toxin-A injections for spastic toe clawing. Parkinsonism Relat Disord, 12: 43–7.
Linder, M., Schindler, G., Michaelis, al. (2001). Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure. Eur J Neurol, 8 (suppl. 5): 120–6.
Ludlow, C. L., Hallett, M., Rhew, al. (1992). Therapeutic uses of type F botulinum toxin (letter). N Engl J Med, 326: 349–50.
Mall, V., Heinen, F., Siebel, al. (2006). Treatment of adductor spasticity with BoNT-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol, 48: 10–13.
Odergren,, T., Hjaltason, H., Kaakkola, al. (1998). A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry, 64: 6–12.
Page, S. J., Elovic, E., Levine, P. & Sisto, S. A. (2003). Modified constraint-induced therapy and botulinum toxin A: a promising combination. Am J Phys Med Rehabil, 82: 76–80.
Pierson, S. H., Katz, D. I. & Tarsy, D. (1996). Botulinum A toxin in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehab, 77: 717–21.
Pittock, S. J., Moore, A. P., Hardiman, al. (2003). A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis, 15: 289–300.
Reeuwijk, A., Shie, P. E. M., Becher, J. G. & Kwakkel, G. (2006). Effects of botulinum toxin type A on upper limb function in children with cerebral palsy: a systematic review. Clin Rehabil, 20: 375–87.
Rosales, R., Arimura, K., Takenaga, S. & Osame, M. (1996). Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve, 19: 488–96.
Sampaio, C., Ferreira, J. J., Pinto, A. al. (1997b). Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients. Clin Rehabil, 11: 3–7.
Sampaio, C., Ferreira, J. J., Simoes, al. (1997a). DYSBOT: a single blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of the formulations of botulinum toxin type A-Dysport and Botox assuming a ratio of 4:1. Mov Disord, 12: 1013–18.
Scott, A. B. (1979). Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology, 87: 1044–9.
Slawek, J., Bogucki, A. & Reclawowicz, D. (2005). Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens. Neurol Sci, 26: 32–9.
Smeulders, M., Coester, A. & Kreulen, M. (2005). Surgical treatment for the thumb-in-palm deformity in patients with cerebral palsy. Cochrane Database Syst Rev, (4): CD004093.
Suputtitada, A. (2002). Local botulinum toxin type A injections in the treatment of spastic toes. Am J Phys Med Rehabil, 81: 770–5.
Truong, D. D., Rontal, M., Rolnick, M., Aronson, A. E. & Mistura, K. (1991). Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope, 101: 630–4.
Tsui, J. K. C., Bhatt, M., Calne, S. & Calne, D. B. (1993). Botulinum toxin in the treatment of writer's cramp: a double-blind study. Neurology, 43: 183–5.
Turkel, C. C., Bowen, B., Liu, J. & Brin, M. F. (2006). Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil, 87: 786–92.
Verplancke, D., Snape, S., Salisbury, C. F., Jones, P. W. & Ward, A. B. (2005). A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil, 19: 117–25.
Wall, S. A., Chait, L. A., Temlett, J. al. (1993). Botulinum A chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg, 46: 703–6.
Ward, A., Roberts, G., Warner, J. & Gillard, S. (2005). Cost-effectiveness of botulinum toxin type A in the treatment of post-stroke spasticity. J Rehabil Med, 37: 252–7.
Ward, A. B. (chairman) et al. (2001). Working Party Report on the Management of Spasticity Using Botulinum Toxin Type A – A Guide to Clinical Practice. Radius Healthcare, Byfleet, UK.
Wasiak, J., Hoare, B. & Wallen, M. (2004). Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev, (4): CD003469.
Westhoff, B., Seller, K., Wild, A., Jaeger, M. & Krauspe, R. (2003). Ultrasound-guided botulinum toxin injection technique for the iliopsoas muscle. Dev Med Child Neurol, 45: 829–32.
Whitaker, J., Butler, A., Semlyen, J. K. & Barnes, M. P. (2001). Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: a comparative study between a home and a clinic treatment service. Arch Phys Med Rehabil, 82: 480–4.
Whurr, R., Lorch, M., Fontana, al. (1993). The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. J Neurol Neurosurg Psychiatry, 56: 526–30.
Wiegand, H., Erdmann, G. & Wellhoner, H. H. (1976). I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Arch Pharmacol, 292: 161–5.
Yang, T. F., Fu, C. P., Kao, N. T., Chan, R. C. & Chen, S. J. (2003). Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. Am J Phys Med Rehabil, 82: 284–9.
Yelnik, A. P., Colle, F. M. & Bonan, I. V. (2003). Treatment of pain and limited movement of the shoulder in hemiplegic patients with botulinum toxin A in the subscapular muscle. Eur Neurol, 50: 91–3.
Zuber, M., Sebald, M., Bathien, N., Recondo, J. & Rondot, P. (1993). Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology, 43: 1715–18.